| Literature DB >> 15900115 |
Abstract
The diagnosis and assignment of grade in neoplasms of the central nervous system (CNS), for the most part, are morphologically based and predicated on the interpretation of descriptions of what the phenotypic findings are for a particular tumor type. Not surprisingly, the application of various grading systems in CNS neoplasia has been limited somewhat by interobserver variability. Since assignment of grade and tumor type is the basis upon which therapeutic intervention is grounded, investigators have been searching for ancillary means by which morphologically based systems can be improved. Utilization of cell proliferation markers in the evaluation of tumors can be potentially useful in this endeavor. This review focuses on issues surrounding the utilization of MIB-1 or Ki-67 antibody in the evaluation of CNS neoplasms.Entities:
Mesh:
Substances:
Year: 2005 PMID: 15900115 DOI: 10.1097/01.pap.0000163957.21409.52
Source DB: PubMed Journal: Adv Anat Pathol ISSN: 1072-4109 Impact factor: 3.875